FDA ‘yes’ for Emgality in cluster headache
In a trial, patients taking Emgality experienced 8.7 fewer weekly cluster headache attacks than they did at baseline.
Read More
Tag: The US Food and Drug Administration
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
